AstraZeneca PLC Earnings - Q1 2026 Analysis & Highlights
AstraZeneca reported strong Q1 2026 financial performance with robust pipeline execution, highlighted by four positive Phase III programs and multiple regulatory approvals, while maintaining confidence in mid-to-high single-digit revenue growth and low-double-digit EPS growth for the full year.
Key Financial Results
Total revenue grew 8% in Q1 2026, supported by robust demand for innovative medicines.
Operating profit increased 12%, reflecting ongoing focus on operating leverage.
Core EPS grew 5% to $2.58, with growth rate impacted by a low tax rate in Q1 2025.
Product revenue increased 8%, with continued growth across all key regions.
Alliance revenue increased 26%, reflecting increased profit shares for partnered products Enhertu and Tezspire.
Core gross margin was 83% in Q1, with expectation of stable to slightly higher core gross margin versus 2025 for the full year.
Cash flow from operating activities was $3.4 billion, a slight decline versus the same period last year due to a large milestone receipt in Q1 2025, but partly offset by strong underlying performance.
Business Segment Results
Oncology total revenues grew 16% to $6.8 billion in Q1, with double-digit growth across all reported geographic segments.
Oncology performance in the US and Europe was particularly strong, with growth of 18% and 19% respectively.
Tagrisso grew 5% to revenues of $1.8 billion, driven by robust demand across all stages of EGFR-mutated lung cancer in the US and Europe, partially offset by higher than historic destocking in the US.
Imfinzi and Imjudo delivered aggregate growth of 28%, with Imfinzi growth of 30% underpinned by robust demand growth across all regions.
Calquence revenues grew 17% to more than $900 million, with double-digit growth in all major regions.
Enhertu delivered growth of 34% in the quarter, balanced across regions, now annualizing as a $5 billion brand on an alliance view.
Biopharmaceuticals total revenue declined 2% to $5.8 billion, with growth in key brands mostly offsetting anticipated headwinds from Brilinta, Farxiga, and roxadustat.
Respiratory & Immunology portfolio was up 7% to $2.3 billion, driven by key brands which grew 18%.
Fasenra delivered strong quarter growth of 11% to reach $483 million, supported by strong uptake in China following NRDL listing.
Breztri generated $353 million in revenue, growing by 13%, and achieved first label expansion beyond COPD with US approval for asthma.
Tezspire delivered $303 million in revenue, representing growth rate of 34%, and is now approved for chronic rhinosinusitis with nasal polyps in all major markets.
CVRM total revenue stood at $3.3 billion, representing a decline of 6%, as the business navigates loss of exclusivity headwinds.
Farxiga total revenue fell 3% to $2.2 billion, with LOE effect seen in established rest of world and with VBP implementation in China.
Rare Disease delivered total revenue of $2.4 billion, up 15% year-over-year, driven by growth in neurology and metabolic diseases.
Ultomiris grew 18%, driven by patient demand across indications including competitive myasthenia gravis and PNH markets.
Strensiq grew 43% year-on-year, reflecting strong underlying demand and favorable comparison versus prior year.
Pipeline and Clinical Development
14 approvals secured in major regions since Q4 2025 results across diverse portfolio.
Four positive Phase III programs announced, including two new molecular entities (NMEs), tozorakimab and efzimfotase alfa.
EMERALD-3 trial demonstrated statistically significant and clinically meaningful improvement in progression-free survival for the STRIDE plus lenvatinib arm in hepatocellular carcinoma, with positive trend to overall survival.
Tozorakimab Phase III LUNA program (OBERON, TITANIA, MIRANDA, and PROSPERO) represents the most comprehensive Phase III program ever conducted for a COPD biologic, with results demonstrating efficacy across broad populations independent of eosinophil levels and lung function severity.
Efzimfotase alfa Phase III program showed meaningful improvements in health and objective endpoints including physical function and quality of life in treatment-naive pediatric HPP patients in MULBERRY trial.
Ultomiris Phase III IgAN trial met primary endpoint, demonstrating statistically significant and clinically meaningful reduction in proteinuria at week 34 in adults with IgAN at risk of disease progression.
Active clinical trials increased by 10%, and number of patients enrolled in studies increased by 30% compared to Q1 last year.
Core R&D expenses increased by 8%, driven by continued acceleration and investment in pipeline.
Capital Allocation
CapEx of $600 million includes previously announced multiyear investments such as new ADC manufacturing facility in Singapore and new manufacturing plant in Qingdao, China for inhaled respiratory portfolio.
CapEx anticipated to increase by around a third in 2026.
Deal payments of $1.1 billion include milestone payments to partners and upfront payment for Jacobio license agreement announced last year.
Milestone payments of around $2.5 billion anticipated for full year relating to past transactions.
Net debt increased by around $2.5 billion in the quarter, driven by payment of second FY 2025 interim dividend in March.
Company is comfortable with current level of gross debt, and anticipates core finance expenses to increase this year driven by higher lease expense and lower interest income.
Geographic Performance
United States grew at double-digit percentage, benefiting from investment behind recent launches.
Europe and emerging markets grew at high-single digits.
Ex-China emerging markets revenues up 9%, reflecting benefit of sustained presence in this market.
China revenues increased by 2%, with VBP implementation impacting Farxiga, Lynparza, and roxadustat growth.
Company confident in growth outlook in China based on positive 2026 NRDL outcomes.
Industry Trends and Dynamics
Strong demand for innovative medicines across AstraZeneca's portfolio.
Oncology and Rare Disease saw strong double-digit growth, while high demand in R&I was offset by loss of exclusivity in CVRM.
COPD remains critical area of unmet medical need, third leading cause of death globally claiming over 3 million lives each year.
Approximately half of COPD patients on inhaled standard of care still experience exacerbations, amplifying risk of cardiovascular events.
Current biologics in COPD primarily for high eosinophils, with studies done above 300s.
Biologic penetration of current biologics in COPD still relatively limited, below 10%.
Treatment landscape for ATTR-CM evolving during CARDIO-TTRansform study, with baseline standard of care treatments including SGLT2 and tafamidis expected to impact event rates.
Competitive Landscape
Tagrisso remains treatment of choice in frontline setting, with increasing proportion of physicians opting for FLAURA2 combination.
Calquence continues to maintain share leadership position in front line CLL setting despite intense competition.
Enhertu showing share gains in both HER2 positive and low breast cancers in China following NRDL enlistment.
Encouraging early signs of adoption of Enhertu in first line HER2-positive breast cancer in US following DESTINY-Breast09 approval.
Fasenra is clearly the leading anti-IL-5 in the class, with EGPA launch in countries like Japan and United States very successful.
NIMBLE study showed long-acting anti-IL-5 not specifically successful regarding switch from Fasenra, with performance even getting worse.
Camizestrant has differentiated asset profile with robust effect size in second-line setting in both ESR mutant and wild-type populations.
Roche's persevERA first-line metastatic ESR1 all-comers trial failed, but AstraZeneca enriched first-line patient population in SERENA-4 to enrich for greater endocrine sensitive population.
Macroeconomic Environment
MFN (Most Favored Nation) pricing provisions affecting future launches in seven major markets, with implementation expected to play out over next 18 months to two years.
Discussions with regulatory authorities ongoing regarding improved access and pricing environment in all countries.
UK already showing movements in discussions based on 301 investigation, with discussions expected to start with other countries in next few weeks or months.
Europe represents 20% of global sales, so impact of pricing pressures is manageable.
Growth Opportunities and Strategies
Multiple future launches planned, including baxdrostat, camizestrant, and tozorakimab.
Continued investment in commercial capabilities to support ongoing launches and multiple future launches.
Continued investment in transformative technologies, including cell therapies and T-cell engagers to drive growth beyond 2030.
Baxdrostat anticipated to launch later in 2026 with PDUFA date for FDA regulatory decision set for Q2, as first aldosterone synthase inhibitor for uncontrolled and resistant hypertension.
Datroway has $5 billion-plus ambition with series of important readouts happening over next several quarters including AVANZAR TL07, TL08, TROPION-Lung15, TROPION-Lung14.
Efzimfotase alfa represents peak sales opportunity of $3 billion to $5 billion, improving upon Strensiq profile with longer half-life, more patient-friendly dosing, and improved manufacturing process.
Ultomiris IgAN indication could reach blockbuster potential given established nephrology presence across AstraZeneca and Alexion, with company seeking accelerated approval in key markets.
Tozorakimab has potential to address broadest population of COPD patients with approximately 6 billion biologic eligible patients globally.
Tozorakimab potential peak sales of $3 billion to $5 billion in COPD alone, with potential for expansion into other indications like bronchiectasis and asthma.
Baxdrostat potential peak sales of $5 billion, with additional potential indications in CKD that could move number up to potentially $10 billion.
Elecoglipron GLP-1 program with comprehensive Phase III development program focused on both weight loss efficacy and outcome benefits to address complex interrelated comorbidities.
AstraZeneca uniquely positioned to create both monotherapies and fixed dose combinations with elecoglipron, including potential combination with SGLT2 inhibitor Farxiga.
AZD0120 CAR-T program developed with FasTCAR process enabling ex vivo growth of cells in three-day process with reliable turnaround time around 16 days, with dual CD19 and BCMA targeting.
Real-time clinical trials collaboration with FDA on TRAVERSE trial with acalabrutinib in mantle cell lymphoma setting, enabling simultaneous notification of adverse events and potential to save time in submissions.
Financial Guidance and Outlook
Total revenue anticipated to increase by mid- to high-single digits percentage for full year 2026.
Core EPS anticipated to increase by low-double-digit percentage at constant exchange rates for full year 2026.
Low-single-digit positive FX impact on total revenue anticipated based on average March exchange rates.
Neutral FX impact on core EPS anticipated based on average March exchange rates.
Core R&D costs expected to be at upper end of low 20s percentage range as percentage of total revenue for full year.
Company well placed to grow through 2030 and beyond with investments undertaken in R&D and behind new launches.
Rich catalyst path across rest of year with volume of high-value readouts notable, collectively pointing to risk-adjusted peak year revenue potential exceeding $10 billion.
Significant wave of approvals expected, including potential first approval of four NMEs and four lifecycle management indications.
